focus -WSS

focus

author：hotspot 2025-09-30 14:27:26 Page View：3784

LONDON — AstraZeneca said Friday an experimental drug tamped down the progression of a certain type of breast cancer in a Phase 3 trial, a win for the company after the same drug produced underwhelming results in a lung cancer trial over the summer.

The drug, called datopotamab deruxtecan or Dato-DXd for short, succeeded on one of its primary endpoints of improving progression-free survival compared to chemotherapy in certain breast cancer patients who had previously been treated with other therapies.

AstraZeneca, which is developing Dato-DXd with partner Daiichi Sankyo, said that the data for the other primary endpoint of overall survival were not “mature” as of this interim analysis, but that there was a positive trend. The trial is continuing.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： A deep dive into Applied Therapeutics’ data, and questions on Cassava
Next article： Anesthesiologist group: stop taking Ozempic before surgery

knowledge

Duchenne breakthrough therapy leaves behind pioneering families

DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

Just how do doctors, lawmakers, and the public define abortion?

Anexamroominawomen'shealthcenterinIndiana,whereabortionsarenowbannedwithverylimitedexceptions.ScottO

Anesthesiologist group: stop taking Ozempic before surgery

EspeciallyinthefirstweeksoftakingdrugslikeOzempic,foodstayslongerinthestomach—aprobleminsurgeries.Ad

Hubble vs. James Webb telescope images: See the difference

2:22NASA'sJamesWebbSpaceTelescoperevealsStephan'sQuintetinanewlight.Avisualgroupingoffivegalaxies,is

focus

comprehensive

knowledge

Hubble vs. James Webb telescope images: See the difference